Ascendis Pharma As Stock Performance
| ASND Stock | USD 144.08 1.59 1.12% |
On a scale of 0 to 100, Ascendis Pharma holds a performance score of 7. The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascendis Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascendis Pharma is expected to be smaller as well. Please check Ascendis Pharma's value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to make a quick decision on whether Ascendis Pharma's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ascendis Pharma AS are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Ascendis Pharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.12 | Five Day Return 3.84 | Year To Date Return 4.41 | Ten Year Return 700.44 | All Time Return 665.16 |
1 | Ascendis Pharma Selects PANTHERx Rare for the Distribution of YORVIPATH | 12/06/2024 |
2 | This Coca-Cola Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Tuesday | 01/07/2025 |
3 | Is Ascendis Pharma the High Growth International Stock to Invest in Now | 01/23/2025 |
4 | Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on ... | 02/05/2025 |
5 | Ascendis Pharma AS Shares Purchased by abrdn plc | 02/06/2025 |
6 | WESTFIELD CAPITAL MANAGEMENT CO LP Increases Stake in Flywire Corp | 02/11/2025 |
7 | Ascendis Pharma AS Posts Earnings Results, Beats Estimates By 0.64 EPS | 02/12/2025 |
8 | Ascendis Pharma targets 200M SKYTROFA revenue and expands YORVIPATH globally in 2025 | 02/13/2025 |
9 | Ascendis Pharma Full Year 2024 Earnings Beats Expectations | 02/14/2025 |
| Begin Period Cash Flow | 392.2 M | |
| Free Cash Flow | -307.6 M |
Ascendis |
Ascendis Pharma Relative Risk vs. Return Landscape
If you would invest 12,438 in Ascendis Pharma AS on November 20, 2024 and sell it today you would earn a total of 1,970 from holding Ascendis Pharma AS or generate 15.84% return on investment over 90 days. Ascendis Pharma AS is currently generating 0.2925% in daily expected returns and assumes 3.0006% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Ascendis, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ascendis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ascendis Pharma AS, and traders can use it to determine the average amount a Ascendis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0975
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ASND | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.0 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Ascendis Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascendis Pharma by adding it to a well-diversified portfolio.
Ascendis Pharma Fundamentals Growth
Ascendis Stock prices reflect investors' perceptions of the future prospects and financial health of Ascendis Pharma, and Ascendis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascendis Stock performance.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 8.93 B | ||||
| Shares Outstanding | 59.84 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 23.71 X | ||||
| Revenue | 363.64 M | ||||
| Gross Profit | 319.38 M | ||||
| EBITDA | (290.02 M) | ||||
| Net Income | (378.08 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 856.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (1.77) X | ||||
| Cash Flow From Operations | (306.2 M) | ||||
| Earnings Per Share | (6.79) X | ||||
| Market Capitalization | 8.62 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.28 B) | ||||
| Working Capital | 153 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
About Ascendis Pharma Performance
By analyzing Ascendis Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascendis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascendis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascendis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.4 K | 4.4 K | |
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (1.03) | (0.97) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | 3.58 | 3.76 |
Things to note about Ascendis Pharma AS performance evaluation
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascendis Pharma AS had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 319.38 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Ascendis Pharma Full Year 2024 Earnings Beats Expectations |
- Analyzing Ascendis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascendis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascendis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascendis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascendis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascendis Pharma's stock. These opinions can provide insight into Ascendis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |